Showing results (251-260 of 369) with videos related to
Sort By:
Pageof 37
JAMA Oncology|July 7, 2018
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical TrialKaren A Autio, Robert Dreicer, Justine Anderson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2004
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancerD Andrew Loblaw, David S Mendelson, James A Talcott, et al.The Prostate|May 10, 2022
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data qualityNiamh M Keegan, Samantha E Vasselman, Ethan S Barnett, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancerMichael J Morris, Neeta Pandit-Taskar, Jorge Carrasquillo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancerMichael J Morris, Chaitanya R Divgi, Neeta Pandit-Taskar, et al.The Lancet. Oncology|October 13, 2012
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage studyDavid Olmos, Daniel Brewer, Jeremy Clark, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2015
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled TrialEthan Basch, Allison M Deal, Mark G Kris, et al.The Prostate|September 1, 2020
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meetingAndrea K Miyahira, Kenneth J Pienta, John W Babich, et al.Clinical Chemistry|February 24, 2009
Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survivalPauliina Helo, Angel M Cronin, Daniel C Danila, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Germline BRCA mutations denote a clinicopathologic subset of prostate cancerDavid J Gallagher, Mia M Gaudet, Prodipto Pal, et al.Pageof 37